Get started
Author

R. Balabanska

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
2021 · Sven M. Francque, Pierre Bedossa, et al. · New England Journal of Medicine · 833
PDF
TLR7 agonist RO7020531 versus placebo in healthy volunteers and patients with chronic hepatitis B virus infection: a randomised, observer-blind, placebo-controlled, phase 1 trial
2022 · Man-Fung Yuen, Rozalina Balabanska, et al. · The Lancet Infectious Diseases · 45
The PanPPAR agonist lanifibranor induces both resolution of NASH and regression of fibrosis after 24 weeks of treatment in non-cirrhotic NASH: results of the NATIVE Phase 2b trial
2020 · Sven Francque, Pierre Bédossa, et al. · Digital Access to Libraries · 22
Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients
2024 · Jinlin Hou, Edward Gane, et al. · Clinical and Molecular Hepatology · 14
PDF
Hepatitis B virus antigen reduction effect of RO7049389 plus NUC with/without Peg-IFN in chronic hepatitis B patients
2022 · Jinlin Hou, Edward J Gane, et al. · Journal of Hepatology · 9
2010 Q2week Controlled-release-interferon-alpha2b + Ribavrin Reduces Flu-like Symptoms >50% and Provides Equivalent Efficacy in Comparison to Weekly Pegylated-interferon-alpha2b + Ribavirin in Treatment-naive-genotype-1-chronic-hepatitis-c: Results From Empower, a Randomized-open-label-12-week-comparison in 133 Patients
2010 · W.A. Long, D. Takov, et al. · Journal of Hepatology · 9
PDF
Viral nucleic acids suppression activity of RO7049389 plus NUC with/without Peg-IFN in virologically-suppressed and naive chronic hepatitis B patients: 48-week treatment and post-treatment follow-up
2022 · Man-Fung Yuen, Rozalina Balabanska, et al. · Journal of Hepatology · 6
No correlation between the alanine aminotransferase (ALT) levelsandthe histological activity index (HAI) in patients withchronichepatitis C
2000 · G. Mechkov, R. Balabanska, et al. · Journal of Hepatology · 4
729 Maintenance Peginterferon Alfa-2a Treatment Reduces Hbsag Level in Genotype D Hbeag-negative Interferon-responders (interim Results)
2011 · Z. Krastev, D. Jelev, et al. · Journal of Hepatology · 2
446 Timing and Frequency of Depression During Hcv-treatment With Controlled-release-ifna2b (cr2b) Vs. Pegylated-ifna2b (peg2b): Results From Select-2, a Randomized-open-label-72-week-comparison in 116 Treatment-naive Patients With Genotype-1 Hcv
2011 · W.A. Long, Z. Younossi, et al. · Journal of Hepatology · 2
PDF
TLR7 agonist ro7020531 triggers immune activation after multiple doses in chronic hepatitis B patients
2018 · E. Gane, K Agarwai, et al. · 1
P019 Regional prevalence of IL28B SNPS rs8099917& rs12979860 in general population and in a cohort of chronic liver diseases patients
2012 · M. Vassilev, R. Balabanska, et al. · Cytokine · 1
Чернодробна стеатоза и неалкохолен стеатохепатит – клинична оценка и приложение на транзиентна еластография (Fibroscan)
2021 · Балабанска, Розалина, Balabanska, Rozalina · Bulgarian Portal for Open Science
Use of noninvasive biomarkers to assess fibrosis regression in cirrhotic patients during nucleos(t)ide therapy
2018 · C. Pan, N. Izumi, et al. · Journal of Hepatology
156 Regional Prevalence of Il28b Snps Rs8099917&rs12979860 in General Population and in a Cohort of Chronic Liver Diseases Patients
2012 · M. Vassilev, R. Balabanska, et al. · Journal of Hepatology
Two Year Tenofovir Disoproxil Fumarate (tdf) Treatment and Adefovir Dipivoxil (adv) Switch Data in Hbeag-negative Patients With Chronic Hepatitis B (study 102), Preliminary Analysis
2008 · GÜREL, SELİM, Dusheiko, Geoff, et al. · Bursa Uludag University - AVESIS
Works count: 17
Citation count: 949
H-index: 6
I10-index: 4
Year
Topic
Type